Date	Name	Title	Type	Shares Traded	Price Range
Mar 22, 2010	aberman michael s	Officer	Acquisition (Non Open Market)	10,000	n/a
Nov 2, 2009	brown michael s	Director	Disposition (Non Open Market)	12,000	n/a
Apr 9, 2010	brown michael s	Director	Acquisition (Non Open Market)	29,662	n/a
Dec 12, 2007	gilman alfred g	Director	Disposition (Non Open Market)	2,000	n/a
Dec 17, 2007	gilman alfred g	Director	Disposition (Non Open Market)	1,500	n/a
Dec 19, 2007	gilman alfred g	Director	Disposition (Non Open Market)	500	n/a
Dec 24, 2007	gilman alfred g	Director	Disposition (Non Open Market)	500	n/a
Dec 19, 2008	gilman alfred g	Director	Disposition (Non Open Market)	1,000	n/a
Dec 21, 2009	gilman alfred g	Director	Disposition (Non Open Market)	8,000	n/a
Dec 23, 2008	gilman alfred g	Director	Acquisition (Non Open Market)	6,000	n/a
Dec 23, 2008	gilman alfred g	Director	Disposition (Non Open Market)	6,000	n/a
Jan 2, 2009	gilman alfred g	Director	Acquisition (Non Open Market)	2,000	n/a
Jan 2, 2009	gilman alfred g	Director	Disposition (Non Open Market)	2,000	n/a
Nov 17, 2009	gilman alfred g	Director	Disposition (Non Open Market)	2,000	n/a
Dec 17, 2007	goldberg murray a	Officer	Disposition (Non Open Market)	200	n/a
Dec 8, 2008	goldberg murray a	Officer	Disposition (Non Open Market)	120	n/a
Aug 11, 2008	goldstein joseph l	Director	Acquisition (Non Open Market)	3,000	n/a
Aug 20, 2008	goldstein joseph l	Director	Disposition (Non Open Market)	2,500	n/a
Nov 20, 2007	roberts william	Officer	Acquisition (Non Open Market)	34,684	n/a
Aug 22, 2008	roberts william	Officer	Acquisition (Non Open Market)	24,102	n/a
Showing 1-20 of 174 transactions Page: 1 2 3 4 5 6 7 8 9  See Next 20

Stock transaction information provided by EDGAR Online. Regeneron Pharmaceuticals, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.